152 related articles for article (PubMed ID: 6096758)
41. Role of endogenously released cholecystokinin in determining postprandial insulin levels in man: effects of loxiglumide, a specific cholecystokinin receptor antagonist.
Baum F; Nauck MA; Ebert R; Cantor P; Hoffmann G; Choudhury AR; Schmidt WE; Creutzfeldt W
Digestion; 1992; 53(3-4):189-99. PubMed ID: 1291406
[TBL] [Abstract][Full Text] [Related]
42. Effects on exocrine and endocrine rat pancreas of long-term administration of CCK-PZ (cholecystokinin-pancreozymin) or synthetic octapeptide - CCK-PZ.
Arnesjö II; Lundquist I
Scand J Gastroenterol; 1976; 11(5):529-35. PubMed ID: 785590
[TBL] [Abstract][Full Text] [Related]
43. Discrepancies between the doses of cholecystokinin or caerulein-stimulating exocrine and endocrine responses in perfused isolated rat pancreas.
Otsuki M; Sakamoto C; Yuu H; Maeda M; Morita S; Ohki A; Kobayashi N; Terashi K; Okano K; Baba S
J Clin Invest; 1979 Mar; 63(3):478-84. PubMed ID: 372241
[TBL] [Abstract][Full Text] [Related]
44. Endogenous nitric oxide mediates pancreatic exocrine secretion stimulated by secretin and cholecystokinin in rats.
Jyotheeswaran S; Li P; Chang TM; Chey WY
Pancreas; 2000 May; 20(4):401-7. PubMed ID: 10824696
[TBL] [Abstract][Full Text] [Related]
45. Arterial gastroduodenal infusion of cholecystokinin-33 stimulates the exocrine pancreatic enzyme release via an enteropancreatic reflex, without affecting the endocrine insulin secretion in pigs.
Rengman S; Weström B; Ahrén B; Pierzynowski SG
Pancreas; 2009 Mar; 38(2):213-8. PubMed ID: 18852685
[TBL] [Abstract][Full Text] [Related]
46. The regulation of insulin and glucagon secretion by opiates: a study with naloxone in healthy humans.
Locatelli A; Spotti D; Caviezel F
Acta Diabetol Lat; 1985; 22(1):25-31. PubMed ID: 3890450
[TBL] [Abstract][Full Text] [Related]
47. Chronic effect of oral cholestyramine, a bile salt sequestrant, and exogenous cholecystokinin on insulin release in rats.
Kogire M; Gomez G; Uchida T; Ishizuka J; Greeley GH; Thompson JC
Pancreas; 1992; 7(1):15-20. PubMed ID: 1557341
[TBL] [Abstract][Full Text] [Related]
48. Effects of cholecystokinin receptor blockade on circulating concentrations of glucose, insulin, C-peptide, and pancreatic polypeptide after various meals in healthy human volunteers.
Niederau C; Schwarzendrube J; Lüthen R; Niederau M; Strohmeyer G; Rovati L
Pancreas; 1992; 7(1):1-10. PubMed ID: 1557335
[TBL] [Abstract][Full Text] [Related]
49. Insulinotropic effects of cholecystokinin, gastric inhibitory polypeptide and glucagon-like peptide-1 during perifusion of short-term cultured canine isolated islets.
van der Burg MP; Guicherit OR; Frölich M; Gooszen HG
Regul Pept; 1995 Dec; 60(1):61-7. PubMed ID: 8747785
[TBL] [Abstract][Full Text] [Related]
50. Treatment with cholecystokinin receptor antagonist loxiglumide enhances insulin response to intravenous glucose stimulation in postpancreatitic rats.
Otsuki M; Nakano S; Tachibana I
Regul Pept; 1994 Jul; 52(2):85-95. PubMed ID: 7972939
[TBL] [Abstract][Full Text] [Related]
51. Stimulatory effects of cholecystokinin on isolated perifused islets inhibited by potent and specific antagonist L 364718 [corrected].
Zawalich WS; Diaz VA; Zawalich KC
Diabetes; 1988 Oct; 37(10):1432-7. PubMed ID: 3046973
[TBL] [Abstract][Full Text] [Related]
52. Endocrine actions of opioids.
Pfeiffer A; Herz A
Horm Metab Res; 1984 Aug; 16(8):386-97. PubMed ID: 6088380
[TBL] [Abstract][Full Text] [Related]
53. Effects of cholecystokinin (CCK-33) and its fragments, C-terminal octapeptide (CCK-8) and C-terminal tetrapeptide (CCK-4), on the circulatory system of diabetic rats.
Fiedorowicz RJ; Wiśniewski K
Pol J Pharmacol Pharm; 1989; 41(6):561-72. PubMed ID: 2485904
[TBL] [Abstract][Full Text] [Related]
54. Effects of intravenous infusions of cholecystokinin (CCK)-8 on exocrine and endocrine pancreatic secretion in conscious sheep.
Mineo H; Iwaki N; Kogishi K; Zabielski R; Onaga T; Kato S
Comp Biochem Physiol A Physiol; 1995 May; 111(1):133-8. PubMed ID: 7537612
[TBL] [Abstract][Full Text] [Related]
55. Effect of a cholecystokinin antagonist on meal-stimulated insulin and pancreatic polypeptide release in humans.
Hildebrand P; Ensinck JW; Ketterer S; Delco F; Mossi S; Bangerter U; Beglinger C
J Clin Endocrinol Metab; 1991 May; 72(5):1123-9. PubMed ID: 2022712
[TBL] [Abstract][Full Text] [Related]
56. Cholecystokinin-GABA interactions in rodent cortex: analyses of cholecystokinin effects on K(+)- and L-glutamate-induced release of [3H]GABA from rat cortical slices and cultured mouse cortical neurones.
Hickling YM; Cheung NS; Larm JA; Cowen MS; Shulkes A; Beart PM
Neurochem Int; 1997 Feb; 30(2):171-9. PubMed ID: 9017664
[TBL] [Abstract][Full Text] [Related]
57. Proglumide analogues CR 1409 and CR 1392 inhibit cholecystokinin-stimulated insulin release more potently than exocrine secretion from the isolated perfused rat pancreas.
Okabayashi Y; Otsuki M; Nakamura T; Fujii M; Tani S; Fujisawa T; Koide M; Hasegawa H; Baba S
Pancreas; 1990 May; 5(3):291-7. PubMed ID: 2188254
[TBL] [Abstract][Full Text] [Related]
58. Dibutyryl guanosine 3',5'-monophosphate inhibits cholecystokinin potentiation of insulin release in the isolated perfused rat pancreas.
Otsuki M; Okabayashi Y; Ohki A; Suehiro I; Oka T; Baba S
Endocrinology; 1986 Jul; 119(1):244-9. PubMed ID: 3013587
[TBL] [Abstract][Full Text] [Related]
59. Stimulation of insulin secretion by peptides analogous to the C-terminal tetrapeptide amide of cholecystokinin.
Ahmad N; Sharma SD; Rastogi AK; Kidwai JR; Mathur KB
Acta Diabetol Lat; 1984; 21(4):361-4. PubMed ID: 6397026
[TBL] [Abstract][Full Text] [Related]
60. Physiological role and localization of cholecystokinin release in dogs.
Konturek SJ; Tasler J; Bilski J; de Jong AJ; Jansen JB; Lamers CB
Am J Physiol; 1986 Apr; 250(4 Pt 1):G391-7. PubMed ID: 2870644
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
